Background
Methods
Participants and Procedure
Instruments
Analysis
Results
Demographics and Clinical Characteristics
Demographic and clinical variables | n (%) or mean (sd) |
---|---|
Age | 39.36 (6.09) |
Sex | |
Male | 26 (96.30%) |
Female | 1 (3.70%) |
Canadian Forces (CF) status | |
Released | 20 (74.07%) |
Still serving | 7 (25.93%) |
Current Work Status | |
Unemployed | 17 (62.96%) |
Working for Pay | 6 (22.22%) |
On Sick Leave from Work | 4 (14.81%) |
Duration of illness | 10.26 (7.38) |
SF-36 Mental component score | 20.22 (10.11) |
SF-36 Physical component score | 32.48 (15.06) |
Dose and Tolerability
Treatment Efficacy
Outcomes | p-value |
---|---|
BDI | |
Difference between baseline and t2 | 0.0179 |
Difference between baseline and t3 | 0.0042 |
Difference between baseline and t4 | <0.0001 |
PCL
| |
Difference between baseline and t2 | 0.0061 |
Difference between baseline and t3 | 0.0016 |
Difference between baseline and t4 | <0.0001 |
Reexperiencing subscale
| |
Difference between baseline and t4 | 0.0020 |
Avoidance subscale
| |
Difference between baseline and t4 | 0.0123 |
Hyperarousal subscale
| |
Difference between baseline and t4 | 0.0043 |
Intake (t1) | 3-month follow-up (t4) | ||||
---|---|---|---|---|---|
Mean (SD) | Median (range) | Mean (SD) | Median (range) | Effect size | |
BDI Total | 30.44 (7.85) | 29 (14 - 44) | 20.67 (10.05) | 19 (3-43) | 1.09 |
PCL Total | 56.11 (12.66) | 55 (34-87) | 46.85 (13.53) | 46 (23-67) | 0.90 |
PCL Reexperiencing | 15.00 (4.42) | 15 (7-25) | 12.61 (4.72) | 12 (5-22) | 0.57 |
PCL Avoidance | 23.40 (5.22) | 23 (14-34) | 21.05 (6.02) | 21 (10-31) | 0.38 |
PCL Hyperarousal | 16.04 (4.02) | 16 (10-22) | 13.96 (4.32) | 14 (5-21) | 0.48 |
Measure | Responders (%) | ||
---|---|---|---|
1-month (t2) (n = 27) | 2-months (t3) (n = 27) | 3-month (t4) (n = 27) | |
PCL | 7(25.93%) | 9(33.33%) | 10(37.04%) |
BDI | 1(3.70%) | 4(14.81%) | 5(18.52%) |